Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Primary Sjögren's Syndrome (ANISE-II)
NCT05383677Phase 2Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Anifrolumab with Placebo (2 arms). Primary endpoint: Composite of Relevant Endpoints for Sjögren's Syndrome at 24 weeks. Status: unknown.
02
Drugs
anifrolumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT05383677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383677.